Health System Reform Crucial For ATMPs
Executive Summary
The difficulties in getting advanced therapies, such as Novartis’ CAR-T therapy Kymriah, to patients have shifted and manufacturing capacity is no longer the biggest issue.
You may also be interested in...
R&D Industry Finds Biosimilar Interchangeability Statement By EU Regulators ‘Concerning’
A joint statement from the European Medicines Agency and Heads of Medicines Agencies on biosimilar interchangeability is “concerning,” says Europe’s R&D-based industry federation, EFPIA.
Slovakia Eases Market Access For Innovative Medicines
Slovakia has introduced a new system for agreeing managed entry agreements that will make it easier for companies to get their innovative medicines to the market.
New WHO Access Platform Could Mean Tiered Pricing In Europe
New platform for finding solutions to increase access to expensive medicines should ensure sustainability of health care systems and pharmaceutical industry and could include tiered pricing models.